High blood pressure treatment linked to less risk for drop in blood pressure upon standing

September 10, 2020

DALLAS, Sept. 10, 2020 -- Treatment to lower high blood pressure did not increase and may have decreased the risk of developing a condition characterized by an extreme drop in blood pressure upon standing, according to new research to be presented Sept. 10-13, 2020, at the virtual American Heart Association's Hypertension 2020 Scientific Sessions. The meeting is a premier global exchange for clinical and basic researchers focusing on recent advances in hypertension research.

A type of low blood pressure, known as orthostatic hypotension, occurs when standing from sitting or lying down. Symptoms include feelings of dizziness or light-headedness and sometimes even fainting. The condition is more common among older adults, however, other factors also can increase the risk, including other conditions, such as heart disease and diabetes, and some medications.

Previously, medications to lower blood pressure were thought to increase the risk for extreme drops in blood pressure upon standing. Individual studies, however, were unable to definitively prove cause and effect. In this study, researchers assessed the results of nine separate studies as a meta-analysis, which can provide more information when analyzed collectively.

"Our findings should challenge the traditional teaching about blood pressure treatment causing orthostatic hypotension, reassuring clinicians about the safety of blood pressure treatment with regard to this condition," said principal investigator Stephen P. Juraschek, M.D., Ph.D., a clinician investigator at Beth Israel Deaconess Medical Center-Harvard Medical School in Boston.

Investigators reviewed three large medical databases -- MEDLINE, EMBASE and CENTRAL --through October 7, 2019, to identify studies that examined the effects of blood pressure medications on orthostatic hypotension. For this analysis, researchers reviewed the health record assessments from nine large clinical trials of 31,043 adults with diagnosed hypertension. Nearly half of participants were women, one-fourth were over age 75 and one in five were African American.

"The study population was diverse, including older adults with a number of chronic conditions associated with cardiovascular disease, like diabetes," Juraschek said. "Nevertheless, the findings were consistent across subgroups."

Almost 50% of the patients were treated more aggressively, either to a lower blood pressure goal or with an active drug versus placebo.

Overall, the risk for low blood pressure upon standing decreased among participants taking medication to lower blood pressure, although the study did not look at what specific types of medication were taken. The greatest decrease in risk occurred among those with the lowest blood pressure upon standing, compared to participants with higher blood pressure on standing. The second-greatest decrease in risk occurred among participants without diabetes compared to those with diabetes.

"Orthostatic hypotension identified in the setting of intensive blood pressure treatment should not be viewed as a reason to decrease or discontinue blood pressure treatment," Juraschek said. "In fact, the finding that more aggressive blood pressure treatment lowered orthostatic hypotension was relatively consistent across the studies."

Several limitations could have affected the study's results. First, inconsistent information was available about symptoms and adverse effects, such as falls or fainting, from low blood pressure upon standing. Another limitation is that some cases of low blood pressure could have been missed, since most measurements occurred after one minute, instead of within the first minute of standing. In addition, measurements occurred only after standing from sitting, not from lying down to standing. Finally, the study did not include information about the classes of blood pressure medication used by participants.
This study is publishing simultaneously in the scientific journal, Annals of Internal Medicine.

Co-authors are Jiun-Ruey Hu, M.D., M.P.H.; Jennifer Cluett, M.D.; Anthony Ishak, Pharm.D.; Carol Mita, M.L.I.S.; Lewis Lipsitz, M.D.; Lawrence J. Appel, M.D., M.P.H.; Nigel Beckett, M.B., Ch.B.; Ruth L. Coleman, M.Sc.; William Cushman, M.D.; Barry R. Davis, M.D., Ph.D.; Greg Grandits, M.S.; Rury R. Holman, F.R.C.P.; Edgar R. Miller III, M.D., Ph.D.; Ruth Peters, Ph.D., M.Sc.; Jan A. Staessen, M.D., Ph.D.; Addison A. Taylor, M.D., Ph.D.; Lutgarde Thijs, M.Sc.; Jackson T. Wright, Jr., M.D., Ph.D.; and Kenneth J. Mukamal, M.D,. M.P.H., M.A. The National Institutes of Health and the National Heart, Lung, and Blood Institute funded the study.

Additional Resources:

Available multimedia is on right column of release link https://newsroom.heart.org/news/high-blood-pressure-treatment-linked-to-less-risk-for-drop-in-blood-pressure-upon-standing?preview=2f2db4ab82906cec1b61830f038766b9

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect Association policy or position. The Association makes no representation or warranty as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https://www.heart.org/en/about-us/aha-financial-information.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public's health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

American Heart Association

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.